Who are we?
Its principal goal is to develop innovating solutions in infectious diseases. The new way for these therapies is “immunomodulation”.
The two main objectives are to develop innovating therapies to struggle against pulmonary infections contracted at the hospital and to deliver a large panel of mouse model developed in-house or customized.
Their Missions are to give an answer to a major issue of public health : antibiotic resistance and In-house predictive and customized in vivo pharmaceutical models in infectious diseases and inflammation provides to pharmaceutical industries, Biotechnology Companies and all other private or academic institutes preclinical solutions to evaluate compounds.